LP
CRSP icon

LMR Partners’s CRISPR Therapeutics CRSP Stock Holding History

LMR Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,300
Closed -$585K – 1557
2026
Q1 		$585K Buy
+12,300
New +$649K ﹤0.01% 1066
2024
Q3 		– Sell
-34,700
Closed -$1.87M – 1336
2024
Q2 		$1.87M Buy
+34,700
New +$2.01M 0.02% 558
2024
Q1 		– Sell
-60,000
Closed -$3.76M – 1186
2023
Q4 		$3.76M Buy
+60,000
New +$3.32M 0.04% 372

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

LMR Partners's CRSP Position: Q2 2026 in Review

LMR Partners held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 5,000 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #1269.

LMR Partners first reported a position in CRSP in Q2 2021 and has held it in 6 quarters since. The position peaked at $972K in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • LMR Partners held 5,000 shares of CRISPR Therapeutics worth $273K as of Q2 2026.
  • LMR Partners left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1269 holding.
  • LMR Partners first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 6 quarters since.
  • LMR Partners's CRISPR Therapeutics position peaked at $972K in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.